Sort
10,766 grants matching “checkpoint inhibitor”
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids
$189,130Russell William Jenkins · Massachusetts General Hospital · K08 · FY2021 · CA
Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products
$189,000William Fenical · University Of California, San Diego · R01 · FY2020 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$188,822Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2022 · CA
Identifying Small Molecule Inhibitors of HdmX using Cell-based Screening
$188,748Mukesh Kumar Agarwal · Cleveland Leukemia Therapeutics, Llc · R43 · FY2009 · CA
Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases
$188,644Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R21 · FY2022 · CA
RNA methylation as a novel effector of SETD2 in kidney cancer
$188,636Keith D Robertson · Mayo Clinic Rochester · R21 · FY2025 · CA
Elucidating the role of tumor cell-intrinsic hypoxia inducible factor (HIF)-1α and HIF-2α pathway activation in tumor immune evasion
$188,592Jonathan A Trujillo · University Of Chicago · K08 · FY2024 · CA
Systemic and Local Immune Function after Pediatric Thermal Injury
$188,460Rajan Thakkar · Research Inst Nationwide Children'S Hosp · K08 · FY2019 · GM
Systemic and Local Immune Function after Pediatric Thermal Injury
$188,460Rajan Thakkar · Research Inst Nationwide Children'S Hosp · K08 · FY2021 · GM
Systemic and Local Immune Function after Pediatric Thermal Injury
$188,460Rajan Thakkar · Research Inst Nationwide Children'S Hosp · K08 · FY2020 · GM
Systemic and Local Immune Function after Pediatric Thermal Injury
$188,460Rajan Thakkar · Research Inst Nationwide Children'S Hosp · K08 · FY2018 · GM
Elucidating the role of tumor cell-intrinsic hypoxia inducible factor (HIF)-1α and HIF-2α pathway activation in tumor immune evasion
$188,421Jonathan A Trujillo · University Of Chicago · K08 · FY2023 · CA
Core C Mouse Model Core
$188,379Alain Charest · Massachusetts General Hospital · P01 · FY2019 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$188,323Brent Allen Hanks · Duke University · R37 · FY2024 · CA
Role of AMPK in melanoma brain metastasis
$188,216Bin Zheng · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Development of Sapacitabine Therapy in Leukemias
$188,182William K Plunkett · University Of Tx Md Anderson Can Ctr · P50 · FY2012 · CA
Development of pHLIP-phosphoantigen conjugates for lymphoma therapy
$188,169Andrew J Wiemer · University Of Connecticut Storrs · R21 · FY2023 · CA
The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies
$188,169Raphael H. Valdivia · Duke University · R21 · FY2020 · CA
The Roles of a Novel Immune-Checkpoint Receptor Complex in Driving T Cell Dysfunction in Cancer
$188,169Li Lily Wang · Cleveland Clinic Lerner Com-Cwru · R21 · FY2022 · CA
scFvPD1-FLT3 CAR T Cells for the Treatment of Relapsed Acute Myeloid Leukemia
$188,138Jianhua Yu · Beckman Research Institute/City Of Hope · R21 · FY2020 · CA
p38 MAP kinase in early thymocyte development
$188,125Mercedes R. Rincon · University Of Vermont & St Agric College · R01 · FY2009 · AI
Project 1: Targeting Metastatic Prostate Cancer Patients with Biallelic Loss of CDK12
$188,052Arul M Chinnaiyan · University Of Michigan At Ann Arbor · P50 · FY2022 · CA
Targeting Ribosomal Biogenesis in Prostate Cancer
$187,895Everardo Macias · Duke University · K22 · FY2018 · CA
The role of extrachromosomal DNA in HER2-amplified breast cancer
$187,887Natasha Elise Weiser · Stanford University · K08 · FY2025 · CA
TARGETING ORIGINS OF REPLICATION WITH CANCER DRUGS
$187,864Roswell Park Cancer Institute Corp · R01 · FY2001 · CA